The Rosiglitazone Debacle: A GP perspective
Most general practitioners learn about advances and changes in
medicines from reading journals and speaking with
pharmaceutical industry representatives. The latter, of
course, should be taken with an appropriate measure of salt.
Over the last three years, it has been interesting listening
to reps either defending Rosiglitazone, suggesting the
'allegations' were spurious and no different to competitors'
products, or the said competitors exploiting the 'debate' to
their own advantage.
The average, seasoned GP, hopefully, only prescribes after
due consideration of the available evidence; and the fact the
machinations, wrangling and vested interests extend to the
very top, should come as no surprise.
Diabetic Lead GP in Biggar
Competing interests: No competing interests